Trial Profile
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 22 Feb 2024 Status changed from active, no longer recruiting to completed.
- 05 Dec 2023 Planned End Date changed from 13 Feb 2024 to 3 Dec 2024.
- 14 Feb 2023 Planned End Date changed from 30 Jun 2023 to 13 Feb 2024.